{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukocyte+Disease&page=18",
    "query": {
      "condition": "Leukocyte Disease",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 618,
    "total_pages": 62,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukocyte+Disease&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukocyte+Disease&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T14:03:40.706Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03366142",
      "title": "Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "LAD1"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2018-07-02",
      "completion_date": "2024-10-17",
      "has_results": false,
      "last_update_posted_date": "2024-10-22",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03366142"
    },
    {
      "nct_id": "NCT07726069",
      "title": "Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cannabinoid Hyperemesis Syndrome"
      ],
      "interventions": [
        {
          "name": "Haloperidol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-11",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07726069"
    },
    {
      "nct_id": "NCT00032513",
      "title": "Genetic Studies of Chronic Active Epstein-Barr Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Active Epstein-Barr Virus"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "1 Year to 120 Years"
      },
      "enrollment_count": 300,
      "start_date": "2002-04-16",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00032513"
    },
    {
      "nct_id": "NCT03656380",
      "title": "Mepo for Eosinophilic Esophagitis (EoE) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EoE",
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "Mepolizumab 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Mepolizumab 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 66,
      "start_date": "2019-03-20",
      "completion_date": "2022-12-09",
      "has_results": true,
      "last_update_posted_date": "2023-08-23",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03656380"
    },
    {
      "nct_id": "NCT02282215",
      "title": "Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Neutropenia",
        "Infection"
      ],
      "interventions": [
        {
          "name": "CLT-008",
          "type": "BIOLOGICAL"
        },
        {
          "name": "G-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cellerant Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2014-12",
      "completion_date": "2017-09-22",
      "has_results": false,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 22,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02282215"
    },
    {
      "nct_id": "NCT05104723",
      "title": "Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Granulomatous Disease",
        "Inflammatory Gastrointestinal Disease",
        "Inflammatory Skin Disease",
        "Inflammatory Lung Disease"
      ],
      "interventions": [
        {
          "name": "XELJANZ (tofacitinib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2022-08-12",
      "completion_date": "2026-05-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05104723"
    },
    {
      "nct_id": "NCT05634746",
      "title": "24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "APT-1011",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        },
        {
          "name": "Esophagogastroduodenoscopy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ellodi Pharmaceuticals, LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 218,
      "start_date": "2022-12-29",
      "completion_date": "2024-08-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-13",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 59,
      "location_summary": "Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05634746"
    },
    {
      "nct_id": "NCT01631591",
      "title": "Prevalence of Food Allergies in a Cohort of Adult Patients With Eosinophilic Esophagitis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Eosinophilic Esophagitis",
        "Food Allergies"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2011-05",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2018-07-10",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01631591"
    },
    {
      "nct_id": "NCT00003597",
      "title": "Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant human thrombopoietin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 16,
      "start_date": "1998-11",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 23,
      "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 16 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003597"
    },
    {
      "nct_id": "NCT02579876",
      "title": "Milk Patch for Eosinophilic Esophagitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Esophagitis",
        "Milk Allergy"
      ],
      "interventions": [
        {
          "name": "Viaskin Milk 500 mcg",
          "type": "DRUG"
        },
        {
          "name": "Viaskin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Years to 17 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-10",
      "completion_date": "2018-11-20",
      "has_results": true,
      "last_update_posted_date": "2019-07-10",
      "last_synced_at": "2026-10-15T14:03:40.706Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579876"
    }
  ]
}